Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.01.2023 | Case report

Ipilimumab/nivolumab/pembrolizumab

Myositis and seropositive myasthenia gravis: 4 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wong EYT, et al. Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: Understanding the diversity in a case series. Asia-Pacific Journal of Clinical Oncology 17: e262-e267, No. 5, Oct 2021. Available from: URL: http://doi.org/10.1111/ajco.13442 Wong EYT, et al. Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: Understanding the diversity in a case series. Asia-Pacific Journal of Clinical Oncology 17: e262-e267, No. 5, Oct 2021. Available from: URL: http://​doi.​org/​10.​1111/​ajco.​13442
Metadaten
Titel
Ipilimumab/nivolumab/pembrolizumab
Myositis and seropositive myasthenia gravis: 4 case reports
Publikationsdatum
01.01.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-30906-8

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Tozinameran

Case report

Aspirin